These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19364952)

  • 1. Phase 0 clinical trials: an answer to drug development stagnation?
    LoRusso PM
    J Clin Oncol; 2009 Jun; 27(16):2586-8. PubMed ID: 19364952
    [No Abstract]   [Full Text] [Related]  

  • 2. Accelerated approval and oncology drug development timelines.
    Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
    J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase 0 trials for anticancer drug development.
    Nat Rev Drug Discov; 2009 Jun; 8(6):442. PubMed ID: 19483703
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of Phase 0 trials in drug development.
    Doroshow JH; Kummar S
    Future Med Chem; 2009 Nov; 1(8):1375-80. PubMed ID: 21426052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials and drug approvals continue to accelerate in China.
    Wang M
    Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trials and methodological problems in prion diseases.
    Puopolo M; Pocchiari M; Petrini C
    Lancet Neurol; 2009 Sep; 8(9):782; author reply 782-3. PubMed ID: 19679270
    [No Abstract]   [Full Text] [Related]  

  • 7. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

  • 10. PARP inhibitors: targeting the right patients.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
    [No Abstract]   [Full Text] [Related]  

  • 11. Vorinostat.
    Grant S; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticancer drug development: moving away from the old habits.
    Ades F; Zardavas D; Aftimos P; Awada A
    Curr Opin Oncol; 2014 May; 26(3):334-9. PubMed ID: 24614094
    [No Abstract]   [Full Text] [Related]  

  • 13. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
    Markman M
    Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
    [No Abstract]   [Full Text] [Related]  

  • 14. Thymidylate synthase inhibitors.
    Ismail AS; Grem JL
    Cancer Chemother Biol Response Modif; 2001; 19():1-19. PubMed ID: 11686010
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug development research: diabetes favored over cardiovascular disease?
    Suckling K
    Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
    [No Abstract]   [Full Text] [Related]  

  • 16. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 17. How can attrition rates be reduced in cancer drug discovery?
    Moreno L; Pearson AD
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase zero launch.
    Dorey E
    Nat Biotechnol; 2009 Jun; 27(6):496. PubMed ID: 19513040
    [No Abstract]   [Full Text] [Related]  

  • 19. Indian government approves 50 clinical trials in one day.
    Kay M
    BMJ; 2013 Jul; 347():f4455. PubMed ID: 23857992
    [No Abstract]   [Full Text] [Related]  

  • 20. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.